Research programme: vacuolar ATPase inhibitors

Drug Profile

Research programme: vacuolar ATPase inhibitors

Alternative Names: BND-002 programme; BND-2 programme; NiK-002 programme; V-ATPase inhibitors programme

Latest Information Update: 19 Apr 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Developer NiKem Research
  • Class Small molecules
  • Mechanism of Action Vacuolar proton translocating ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Postmenopausal osteoporosis

Most Recent Events

  • 30 Nov 2008 Undisclosed company acquires BND 002 programme from Brane
  • 04 Feb 2008 Preclinical development is ongoing for Cancer
  • 03 Oct 2006 This programme is still in active development for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top